A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks

Neurology

Volumn 51, Issue 3, 1998, Pages 773-781

  Kramer, Mark S ^a   Matzura Wolfe, D ^a   Polis, A ^a   Getson, A ^a   Amaraneni, P G ^b   Solbach, M Patricia ^b   McHugh, W ^c   Feighner, J ^d   Silberstein, S ^e   Reines, S A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b MENNINGER CLINIC   (United States)

^c CATC Research   (United States)

^d Feighner Research Institute   (United States)

^e JEFFERSON HEADACHE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIZATRIPTAN; SEROTONIN 1B AGONIST; SEROTONIN 1D RECEPTOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIGRAINE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; VERTIGO;

EID: 0031751088     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.51.3.773     Document Type: Article

References (25)

1. Stewart WF, Shecter A, Rasmussen BK. Migraine prevalence. A review of population-based studies. Neurology 1994; 44(suppl 4):S17-S23.
2. Henry P, Michel P, Brochet B, et al. A nationwide survey of migraine in France. Prevalence and clinical features in adults. Cephalalgia 1992;12:229-237.
3. Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia 1992;12: 221-228.
4. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relations to age, income, race and other sociodemographic factors. JAMA 1992; 267:64-69.
5. Pryse-Phillips W, Findlay H, Tugwell P, Edmeads J, Murray TJ, Nelson RF. A Canadian population survey on the clinical, epidemiologic, and societal impact of migraine and tension type headache, part II. Can J Neurol Sci 1992;19:333-339.
6. Ferrari MD, Odink J, Tapparelli C, van Kempen GMJ, Pennings EJM, Bruyn GW. Serotonin metabolism in migraine. Neurology 1989;98:1239-1242.
7. Saxena PR, Ferrari MD. 5-HT1-like receptor agonists and the pathophysiology of migraine. Trends Pharmacol Sci 1989;10: 200-204.
8. Ferrari MD, Saxena PR. On serotonin and migraine: a clinical and pharmacological review. Cephalalgia 1993;13:151-165.
9. 1D receptor agonist predicts antimigraine efficacy. Headache 1991;31: 228-231.
10. Plosker GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994;47:622-651.
11. Oral Sumatriptan Dose-Defining Study Group. Sumatriptan - an oral dose-defining study. Eur Neurol 1991;31: 300-305.
12. 1D agonist. Clin Pharmacol Ther 1994;55:129. Abstract.
13. Visser WH, Terwindt G, Reines S, Jiang K, Lines C, Ferrari M. Rizatriptan versus sumatriptan in the acute treatment of migraine. Arch Neurol 1996;53:1132-1137.
14. Gijsman H, Kramer M, Sargent J, et al. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia 1997;17:647-651.
15. Teall JH, Tuchman M, Cutler N, et al. Rizatriptan (MAXALT) for the acute migraine and migraine recurrence. A placebo-controlled, outpatient study. Headache 1998;38:281-287.
16. Nappi G, Sicuteri F, Byrne M, Roncolato M, Zerbini O. Film-coated oral sumatriptan compared with placebo in the acute treatment of migraine. J Neurol 1994;241:138-144.
17. Oral Sumatriptan International Multiple-Dose Study Group Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol 1991;31:306-313.
18. Banerjee M, Findley LJ. Sumatriptan in the treatment of acute migraine with aura. Cephalalgia 1992;12:39-44.
19. Goadsby PJ, Zagami AS, Donna GA, et al. Oral sumatriptan in acute migraine. Lancet 1991;338:782-783.
20. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia 1988;8:19-28.
21. Hartmaier S, Santanello N, Epstein R, Silberstein S. Development of a brief 24-hour migraine specific quality of life questionnaire. Headache 1995;35:320-329.
22. Santanello N, Hartmaier S, Epstein R, Silberstein S. Validation of a new quality of life questionnaire for acute migraine headache. Headache 1995;35:330-337.
23. Liang K, Zeger S. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
24. Zeger S, Liang K. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-130.
25. Block GA, Kramer MS, Matzura-Wolfe D, et al. Long-term exposure to rizatriptan 5-mg and 10-mg oral tablets. Headache 1997;37:302. Abstract.